References
- Surveillance, Epidemiology and End Results Program . Cancer stat facts: kidney and renal pelvis cancer. https://seer.cancer.gov/statfacts/html/kidrp.html
- Wan X , ZhangY , TanC , ZengX , PengL. First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost–effectiveness analysis. JAMA Oncol.5(4), 491–496 (2019).
- Capitanio U , MontorsiF. Renal cancer. Lancet387(10021), 894–906 (2016).
- Motzer RJ , EscudierB , McdermottDFet al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med.373(19), 1803–1813 (2015).
- Choueiri TK , EscudierB , PowlesTet al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol.17(7), 917–927 (2016).
- Choueiri TK , PowlesT , BurottoMet al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med.384(9), 829–841 (2021).
- Lheureux S , MateiD , KonstantinopoulosPAet al. A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. J. Clin. Oncol.38(15), 6010 (2020).
- US FDA . FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma (2021). www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-plus-cabozantinib-advanced-renal-cell-carcinoma
- National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology: kidney cancer version 4 (2021). www.nccn.org/professionals/physiciangls/pdf/kidney.pdf
- Centers for Medicare and Medicaid Services . ASP drug pricing files (2021). www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2021ASPFiles.html
- Swallow E , MessaliA , GhateS , McDonaldE , DuchesneauE , PerezJR. The additional costs per month of progression-free survival and overall survival: an economic model comparing everolimus with cabozantinib, nivolumab, and axitinib for second-line treatment of metastatic renal cell carcinoma. J. Manag. Care Spec. Pharm.24(4), 335–343 (2018).
- Hu S , DengX , MaY , LiZ , WangY , WangY. Cost-utility analysis of dapagliflozin versus saxagliptin treatment as monotherapy or combination therapy as add-on to metformin for treating type 2 diabetes mellitus. Appl. Health Econ. Health Policy19(1), 69–79 (2021).
- Rui M , WangY , FeiZ , ZhangX , ShangY , LiH. Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments. Expert Rev. Pharmacoecon. Outcomes Res.21(3), 373–380 (2021).
- US FDA . FDA approved drug products: labels for INLYTA (axitinib) tablets. www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf
- US FDA . FDA approved drug products: labels for OPDIVO (nivolumab). www.accessdata.fda.gov/drugsatfdadocs/label/2019/125554s070lbl.pdf
- US FDA . FDA approved drug products: labels for CABOMETYX (cabozantinib) tablets. www.accessdata.fda.gov/drugsatfdadocs/label/2019/208692s003lbl.pdf
- Diaby V , AdunlinG , MonteroAJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics32(2), 101–108 (2014).
- Guyot P , AdesAE , OuwensMJNM , WeltonNJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med. Res. Methodol.12(1), 9 (2012).
- Latimer NR . Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med. Decis. Making33(6), 743–754 (2013).
- Arias E , HeronM , XuJ. United States life tables, 2018. Natl Vital Stat. Rep.69(12), 1–45 (2020).
- Su Y , FuJ , DuJ , WuB. First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost–effectiveness analysis. Ther. Adv. Med. Oncol.12, 1758835920950199 (2020).
- Centers for Medicare and Medicaid Services . License for use of current procedural terminology, fourth edition (“CPT®”). www.cms.gov/medicare/physician-fee-schedule/search?Y=0&T=0&HT=0&CT=3&H1=96413&M=5
- US Bureau of Labor Statistics . The Consumer Price Index. data.bls.gov/cgi-bin/cpicalc.pl
- De Groot S , RedekopWK , VersteeghMMet al. Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Qual. Life Res.27(1), 115–124 (2018).
- Zhu J , ZhangT , WanNet al. Cost–effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma. Immunotherapy12(17), 1237–1246 (2020).
- Neumann PJ , CohenJT , WeinsteinMC. Updating cost–effectiveness – the curious resilience of the $50,000-per-QALY threshold. N. Engl. J. Med.371(9), 796–797 (2014).
- Briggs AH , WeinsteinMC , FenwickEA , KarnonJ , SculpherMJ , PaltielAD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med. Decis. Making32(5), 722–732 (2012).
- Hoyle M , GreenC , Thompson-CoonJet al. Cost–effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma. Value Health13(1), 61–68 (2010).
- Chiang CL , ChanSK , LeeSF , WongIO , ChoiHC. Cost–effectiveness of pembrolizumab as a second-line therapy for hepatocellular carcinoma. JAMA Netw. Open4(1), e2033761 (2021).
- Gao L , LiSC. Modelled economic evaluation of nivolumab for the treatment of second-line advanced or metastatic squamous non-small-cell lung cancer in Australia using both partition survival and markov models. Appl. Health Econ. Health Policy17(3), 371–380 (2019).
- Attema AE , BrouwerWBF , ClaxtonK. Discounting in economic evaluations. Pharmacoeconomics36(7), 745–758 (2018).
- Rini BI , PlimackER , StusVet al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med.380(12), 1116–1127 (2019).
- Ding D , HuH , ShiYet al. Cost–effectiveness of pembrolizumab plus axitinib versus sunitinib as first-line therapy in advanced renal cell carcinoma in the U.S. Oncologist26(2), e290–e297 (2021).